NASDAQ · QTTB
Q32 Bio Inc.
$8.71-$0.16 (-1.8%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
Loading market information…
NASDAQ · AWH · USD
Stock price, dividends, earnings
Quote as of Feb 10, 2026, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aspira Women's Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Aspira Women's Health Inc.’s forward annual dividend is $1.04 per share, paid quarterly. The forward yield is 1,268.29% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aspira Women's Health Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aspira Women's Health Inc., alongside its subsidiaries, specializes in the development and commercialization of diagnostic tools for gynecologic diseases across the United States. Their product portfolio includes tests such as OVA1, OVERA, and OVA1plus, designed to evaluate the risk of ovarian malignancy in women presenting with adnexal masses. Additionally, they provide ASPiRA GenetiX, a genetic screening option for assessing individual susceptibility to gynecologic cancers. The company operates Aspira Synergy, a cloud-based platform enabling decentralized access to protein biomarker and hereditary genetic testing. Furthermore, Aspira owns and manages ASPiRA LABS, a specialized laboratory dedicated to applying advanced biomarker technologies for the management of gynecologic cancers and related conditions. Its innovation pipeline features upcoming products like OVAWatch, EndoCheck, and OVAInherit. Aspira serves a diverse clientele, including individual physicians, physician office laboratories, and both national and regional laboratory networks. The company actively collaborates with several institutions, holding a research agreement with Baylor Genetics and another with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to explore microRNA technology for enhanced early ovarian cancer detection. A strategic alliance is also in place with Quest Diagnostics, Incorporated. Incorporated in 1993 and headquartered in Austin, Texas, the company adopted its current name, Aspira Women's Health Inc., in June 2020, having previously operated as Vermillion, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| $2.15M-15.9% vs estimate |
| Q4 2023 | Mar 28, 2024 | -$0.30+23.08% vs estimate | $2.13M-16.14% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.71-$0.16 (-1.8%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$5.62+$1.35 (+31.62%)
Applied DNA Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.24% below the high.
$0.00$0.00 (0.0%)
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.04-$0.01 (-13.39%)
Aravive, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$1.80-$1.37 (-43.22%)
MedAvail Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.39% below the high.
$0.09-$0.03 (-24.84%)
Novan, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.17% below the high.
$6.60-$0.16 (-2.38%)
SeqLL Inc.: Healthcare · Medical - Diagnostics & Research.
€0.03-€0.00 (-8.38%)
Biophytis S.A.’s quoted price sits in the lower half of its reported 52-week range, 80.88% below the high.
